IN2013MU02285A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02285A
IN2013MU02285A IN2285MU2013A IN2013MU02285A IN 2013MU02285 A IN2013MU02285 A IN 2013MU02285A IN 2285MU2013 A IN2285MU2013 A IN 2285MU2013A IN 2013MU02285 A IN2013MU02285 A IN 2013MU02285A
Authority
IN
India
Prior art keywords
provides
improved process
monoclonal antibodies
present
desired profile
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjeev Kumar Mendiratta
Sanjay Bandyopadhyay
Sanjay Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2016000123A priority Critical patent/MX2016000123A/es
Priority to CN201480038458.4A priority patent/CN105431454A/zh
Priority to EA201690171A priority patent/EA201690171A1/ru
Priority to SG11201510342VA priority patent/SG11201510342VA/en
Priority to IN2285MU2013 priority patent/IN2013MU02285A/en
Priority to JP2016522968A priority patent/JP2016526385A/ja
Priority to AU2014288811A priority patent/AU2014288811B2/en
Priority to EP14789418.2A priority patent/EP3019528A1/en
Priority to ARP140102519A priority patent/AR096839A1/es
Priority to BR112015032800A priority patent/BR112015032800A2/pt
Priority to TW103123312A priority patent/TW201514305A/zh
Priority to PCT/IN2014/000450 priority patent/WO2015004679A1/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to US14/903,093 priority patent/US20160215319A1/en
Priority to HK16106205.0A priority patent/HK1218297A1/zh
Priority to NZ715246A priority patent/NZ715246A/en
Priority to CA2917484A priority patent/CA2917484A1/en
Publication of IN2013MU02285A publication Critical patent/IN2013MU02285A/en
Priority to IL243011A priority patent/IL243011A0/en
Priority to ZA2015/09334A priority patent/ZA201509334B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN2285MU2013 2013-07-06 2014-07-07 IN2013MU02285A (enExample)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CN201480038458.4A CN105431454A (zh) 2013-07-06 2014-07-07 用于生产单克隆抗体的改进方法
EA201690171A EA201690171A1 (ru) 2013-07-06 2014-07-07 Улучшенный способ получения моноклональных антител
SG11201510342VA SG11201510342VA (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07
JP2016522968A JP2016526385A (ja) 2013-07-06 2014-07-07 モノクローナル抗体の改良された産生方法
AU2014288811A AU2014288811B2 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
EP14789418.2A EP3019528A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
BR112015032800A BR112015032800A2 (pt) 2013-07-06 2014-07-07 “processo para a produção de um anticorpo”
ARP140102519A AR096839A1 (es) 2013-07-06 2014-07-07 Proceso mejorado para la producción de anticuerpos monoclonales
MX2016000123A MX2016000123A (es) 2013-07-06 2014-07-07 Procedimiento mejorado para la produccion de anticuerpos monoclonales.
PCT/IN2014/000450 WO2015004679A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
TW103123312A TW201514305A (zh) 2013-07-06 2014-07-07 製造單株抗體之改良方法
US14/903,093 US20160215319A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
HK16106205.0A HK1218297A1 (zh) 2013-07-06 2014-07-07 用於生产单克隆抗体的改进方法
NZ715246A NZ715246A (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
CA2917484A CA2917484A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
IL243011A IL243011A0 (en) 2013-07-06 2015-12-21 An improved process for the production of monoclonal antibodies
ZA2015/09334A ZA201509334B (en) 2013-07-06 2015-12-22 Improved process for production of monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07

Publications (1)

Publication Number Publication Date
IN2013MU02285A true IN2013MU02285A (enExample) 2015-06-19

Family

ID=51794933

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07

Country Status (18)

Country Link
US (1) US20160215319A1 (enExample)
EP (1) EP3019528A1 (enExample)
JP (1) JP2016526385A (enExample)
CN (1) CN105431454A (enExample)
AR (1) AR096839A1 (enExample)
AU (1) AU2014288811B2 (enExample)
BR (1) BR112015032800A2 (enExample)
CA (1) CA2917484A1 (enExample)
EA (1) EA201690171A1 (enExample)
HK (1) HK1218297A1 (enExample)
IL (1) IL243011A0 (enExample)
IN (1) IN2013MU02285A (enExample)
MX (1) MX2016000123A (enExample)
NZ (1) NZ715246A (enExample)
SG (1) SG11201510342VA (enExample)
TW (1) TW201514305A (enExample)
WO (1) WO2015004679A1 (enExample)
ZA (1) ZA201509334B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110799A1 (en) * 2013-10-18 2015-04-23 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9067990B2 (en) * 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US20160145331A1 (en) * 2012-04-20 2016-05-26 Abbvie Inc. Cell culture methods to reduce acidic species

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
WO2025160161A1 (en) * 2024-01-23 2025-07-31 Amgen Inc. Methods for modulating monoclonal antibody charge variants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2011019619A1 (en) * 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9045536B2 (en) * 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
CA2795461C (en) * 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145331A1 (en) * 2012-04-20 2016-05-26 Abbvie Inc. Cell culture methods to reduce acidic species
US9683033B2 (en) * 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) * 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US20150110799A1 (en) * 2013-10-18 2015-04-23 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150140006A1 (en) * 2013-10-18 2015-05-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150259410A1 (en) * 2013-10-18 2015-09-17 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9200070B2 (en) * 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9200069B2 (en) * 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same

Also Published As

Publication number Publication date
HK1218297A1 (zh) 2017-02-10
JP2016526385A (ja) 2016-09-05
AU2014288811B2 (en) 2017-06-08
ZA201509334B (en) 2017-03-29
MX2016000123A (es) 2016-07-14
EA201690171A1 (ru) 2016-06-30
IL243011A0 (en) 2016-03-31
NZ715246A (en) 2017-07-28
CA2917484A1 (en) 2015-01-15
CN105431454A (zh) 2016-03-23
WO2015004679A1 (en) 2015-01-15
SG11201510342VA (en) 2016-01-28
US20160215319A1 (en) 2016-07-28
TW201514305A (zh) 2015-04-16
AU2014288811A1 (en) 2016-01-28
BR112015032800A2 (pt) 2017-07-25
EP3019528A1 (en) 2016-05-18
AR096839A1 (es) 2016-02-03

Similar Documents

Publication Publication Date Title
NZ715246A (en) Improved process for production of monoclonal antibodies
AR096713A1 (es) Proceso de purificación para anticuerpos monoclonales
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
SG10201805291TA (en) Production of heterodimeric proteins
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
BR112014018961A8 (pt) Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
ZA201703241B (en) Anti-c5 antibodies and methods of use
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
MX366647B (es) Cambio de temperatura para una expresión con mayor rendimiento de polipéptidos en levaduras y otras células transformadas.
MX2015010427A (es) Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
MA40021A (fr) Processus de culture cellulaire destiné à produire une protéine
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
NZ703973A (en) Complex chromosome engineering for production of human antibodies in transgenic animals
MX2015010428A (es) Anticuerpos anti-her2 altamente galactosilados y sus usos.
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
HK1209133A1 (en) Process for reducing antibody aggregate levels and antibodies produced thereby
IN2014DN09097A (enExample)
EP2683740A4 (en) GENERATION OF ANTI-FN14 MONOCLONAL ANTIBODIES BY ACCELERATED DEVELOPMENT OF EX-VIVO ANTIBODIES
EA028913B9 (ru) Получение антител высокой чистоты в pichia pastoris
AU2016219622A1 (en) Heterodimeric antibody FC-containing proteins and methods for production thereof
UA72336U (uk) СПОСІБ ОДЕРЖАННЯ НАНОКРИСТАЛІЧНИХ МАТЕРІАЛІВ НА ОСНОВІ Al З ПІДВИЩЕНОЮ МІКРОТВЕРДІСТЮ